Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.

about

Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.Diagnostic Approaches for Invasive Aspergillosis-Specific Considerations in the Pediatric Population.

P2860

Q40140001-8755963B-FFDC-4420-A69F-47E337B5D5F0 Q52720488-8164DD44-923C-4B45-A0A3-714296761E6B

P2860

Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.

Item

http://www.wikidata.org/entity/Q39127825

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Prognostic value of galactoman ...... s with invasive aspergillosis.

@en

Prognostic value of galactoman ...... s with invasive aspergillosis.

@nl

type

Item

label

Prognostic value of galactoman ...... s with invasive aspergillosis.

@en

Prognostic value of galactoman ...... s with invasive aspergillosis.

@nl

prefLabel

Prognostic value of galactoman ...... s with invasive aspergillosis.

@en

Prognostic value of galactoman ...... s with invasive aspergillosis.

@nl

P1476

Prognostic value of galactoman ...... s with invasive aspergillosis.

@en

P2093

Amit V Desai

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis

Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing

Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.

Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.

Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.

The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.

P2888

s10928-017-9509-1

P304

143-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10928-017-9509-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

William Hope

Laura Kovanda

P577

2017-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28181136

http://www.w3.org/2001/XMLSchema#string

P921

aspergillosis

Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.

about

P2860

P2860

Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921